middle.news
Mesoblast Completes 350-Patient Phase 3 Trial for Low Back Pain Therapy
10:00am on Monday 17th of August, 2026 AEST
•
Healthcare
Read Story
Mesoblast Completes 350-Patient Phase 3 Trial for Low Back Pain Therapy
10:00am on Monday 17th of August, 2026 AEST
Key Points
Phase 3 trial enrollment exceeds target with 350 patients treated
Primary endpoint focuses on durable pain reduction at 12 months
Secondary endpoints include function, quality of life, and opioid cessation
Rexlemestrocel-L holds FDA RMAT designation for priority review
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Mesoblast (ASX:MSB)
OPEN ARTICLE